Safety Evaluation of the ADAM System
Primary Purpose
Azoospermia, Oligospermia
Status
Recruiting
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
ADAM System
Sponsored by
About this trial
This is an interventional device feasibility trial for Azoospermia
Eligibility Criteria
Inclusion Criteria:
- The subject is male
- Subject is 25 to 65 years of age
- Subject has a normal semen analysis (≥ 15 million sperm/mL, ≥40% total motility) defined by the WHO Laboratory Manual for the Examination and Processing of Human Semen (5th Edition), based on the average of two semen samples ≥2 days and ≤7 days apart
- Subject is suitable to undergo a vasectomy as a long-term form of contraception
- Subject is legally competent
- In the opinion of the Investigator, the subject is willing and able to comply with the protocol, return for all follow-up visits and complete all protocol assessments, which includes providing recurring semen samples
- Subject agrees to use an alternative method of contraception with any female partner of reproductive age during the course of the study treatment until study exit occurs
- Subject is willing to accept an unknown risk of conceiving a pregnancy during the duration of the study.
- The subject has been informed of the nature of the study, agrees to its provisions, and has willingly provided written informed consent, approved by the appropriate Human Research Ethics Committee (HREC) -
Exclusion Criteria:
Potential subjects will be excluded if ANY of the following criteria apply:
- Subject is participating in another interventional clinical trial currently or within the past 3 months from the time of screening
- Subject has history of prior hormonal therapy use (e.g., androgenic steroids, GnRH agonists and antagonists) within the past 6 months
- Subject on exam has any of the following: vas not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or intrascrotal mass that would make the subject not suitable for the study
- Subject has allergic reaction to polyethylene glycol (PEG) containing products or has had a prior severe allergic response to injectable or implantable devices
- Subject has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be admitted after resolution of an acute infection
- Subject has current coagulopathy or other bleeding disorders
- Subject currently taking or planning to take any type of systemic medication which could affect sperm count or ejaculation (e.g., anabolic steroids, chemotherapy, alpha blocker)
- Subject had a previous successful or unsuccessful vasectomy or vasectomy reversal
- Subject has any clinically significant abnormal findings or other findings identified by Investigator that would exclude the subject.
Sites / Locations
- Epworth HealthCareRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
ADAM System
Arm Description
All subjects who consent and meet inclusion and none of the exclusion will be enrolled and receive the ADAM System, which is a hydrogel device implanted into the vas deferens.
Outcomes
Primary Outcome Measures
Adverse Events
The primary endpoint is the number of all treatment-emergent adverse events
Secondary Outcome Measures
Serious AEs
Number and percentage of subjects experiencing procedure and device-related serious adverse events at 30 days
Adverse Events of Interest
Number and percentage of subjects experiencing an adverse event of interest during the study
Azoospermia
Percentage of subjects achieving absolute azoospermia, defined as a zero sperm count, and percentage of subjects achieving virtual azoospermia, defined as a sperm count of ≤100,000 per mL and 0% motility
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05134428
Brief Title
Safety Evaluation of the ADAM System
Official Title
Open-label, Single Arm, Multi-Centre, Prospective First-in-Human Study to Assess the Safety of the ADAM™ System
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 7, 2022 (Anticipated)
Primary Completion Date
June 30, 2025 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Contraline, Inc
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will evaluate the safety and feasibility of the ADAM System for implantation into the vas deferens in 25 healthy males at 2 sites. This is a prospective, non-randomized, open label interventional trial.
Detailed Description
There are two cohorts to monitor safety in this study:
Cohort 1: The first 10 subjects will be reviewed for safety by a Data Safety Monitoring Board (DSMB) at 30 days post-implantation. The 10 subjects will then be followed up to 36 months or until the average of two semen analyses is ≥ 15 million sperm/mL (the duration between collection of both specimens is ≥2 days and ≤7 days).
Cohort 2: An additional 15 subjects will be enrolled and implanted with ADAM after the DSMB Safety Review of the first 10 subjects at 30 days. They will be followed up to 36 months or until the average of two semen analyses is ≥ 15 million sperm/mL (the duration between collection of both specimens is ≥2 days and ≤7 days).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Azoospermia, Oligospermia
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ADAM System
Arm Type
Experimental
Arm Description
All subjects who consent and meet inclusion and none of the exclusion will be enrolled and receive the ADAM System, which is a hydrogel device implanted into the vas deferens.
Intervention Type
Device
Intervention Name(s)
ADAM System
Intervention Description
The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
Primary Outcome Measure Information:
Title
Adverse Events
Description
The primary endpoint is the number of all treatment-emergent adverse events
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
Serious AEs
Description
Number and percentage of subjects experiencing procedure and device-related serious adverse events at 30 days
Time Frame
30 Days
Title
Adverse Events of Interest
Description
Number and percentage of subjects experiencing an adverse event of interest during the study
Time Frame
3 years
Title
Azoospermia
Description
Percentage of subjects achieving absolute azoospermia, defined as a zero sperm count, and percentage of subjects achieving virtual azoospermia, defined as a sperm count of ≤100,000 per mL and 0% motility
Time Frame
3 years
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
The subject is male
Subject is 25 to 65 years of age
Subject has a normal semen analysis (≥ 15 million sperm/mL, ≥40% total motility) defined by the WHO Laboratory Manual for the Examination and Processing of Human Semen (5th Edition), based on the average of two semen samples ≥2 days and ≤7 days apart
Subject is suitable to undergo a vasectomy as a long-term form of contraception
Subject is legally competent
In the opinion of the Investigator, the subject is willing and able to comply with the protocol, return for all follow-up visits and complete all protocol assessments, which includes providing recurring semen samples
Subject agrees to use an alternative method of contraception with any female partner of reproductive age during the course of the study treatment until study exit occurs
Subject is willing to accept an unknown risk of conceiving a pregnancy during the duration of the study.
The subject has been informed of the nature of the study, agrees to its provisions, and has willingly provided written informed consent, approved by the appropriate Human Research Ethics Committee (HREC) -
Exclusion Criteria:
Potential subjects will be excluded if ANY of the following criteria apply:
Subject is participating in another interventional clinical trial currently or within the past 3 months from the time of screening
Subject has history of prior hormonal therapy use (e.g., androgenic steroids, GnRH agonists and antagonists) within the past 6 months
Subject on exam has any of the following: vas not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or intrascrotal mass that would make the subject not suitable for the study
Subject has allergic reaction to polyethylene glycol (PEG) containing products or has had a prior severe allergic response to injectable or implantable devices
Subject has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be admitted after resolution of an acute infection
Subject has current coagulopathy or other bleeding disorders
Subject currently taking or planning to take any type of systemic medication which could affect sperm count or ejaculation (e.g., anabolic steroids, chemotherapy, alpha blocker)
Subject had a previous successful or unsuccessful vasectomy or vasectomy reversal
Subject has any clinically significant abnormal findings or other findings identified by Investigator that would exclude the subject.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tammy Clark, MPH
Phone
(434) 218-6668
Email
tammy@contraline.com
First Name & Middle Initial & Last Name or Official Title & Degree
Kevin Eisenfrats
Phone
(434) 218-6668
Email
kevin@contraline.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin Eisenfrats
Organizational Affiliation
Contraline, Inc
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Nathan Lawrentschuk, MB, BS, PhD, FRACS
Organizational Affiliation
Epworth Healthcare
Official's Role
Principal Investigator
Facility Information:
Facility Name
Epworth HealthCare
City
E. Melbourne
State/Province
Victoria
ZIP/Postal Code
3002
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Zhang
Email
ctc-urorenal@epworth.org.au
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Safety Evaluation of the ADAM System
We'll reach out to this number within 24 hrs